Driehaus Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Driehaus Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-94,945	Closed	-$9.68M	–	462
2023 Q2	$9.68M	Buy	+94,945	New	+$8.98M	0.12%	218
2020 Q2	–	Sell	-12,558	Closed	-$1.81M	–	493
2020 Q1	$1.81M	Sell	12,558 -3,740	-23%	-$722K	0.06%	239
2019 Q4	$3.33M	Sell	16,298 -197,077	-92%	-$36M	0.09%	225
2019 Q3	$17.1M	Sell	213,375 -23,264	-10%	-$1.97M	0.56%	45
2019 Q2	$22.3M	Buy	236,639 +91,817	+63%	+$7.93M	0.7%	34
2019 Q1	$12.4M	Buy	144,822 +16,523	+13%	+$1.37M	0.46%	60
2018 Q4	$7.2M	Sell	128,299 -58,528	-31%	-$3.57M	0.31%	94
2018 Q3	$15.3M	Buy	+186,827	New	+$13.2M	0.47%	57

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Driehaus Capital Management's RETA Position: Q3 2023 in Review

Driehaus Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 94,945 shares — an estimated $9.68M sold.

Driehaus Capital Management first reported a position in RETA in Q3 2018 and held it in 8 quarters. The position peaked at $22.3M in Q2 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Driehaus Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Driehaus Capital Management sold 94,945 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $9.68M.
Driehaus Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 8 quarters.
Driehaus Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $22.3M in Q2 2019.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Driehaus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.